Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
04/23/15
ARIAD to Webcast Conference Call on First Quarter 2015 Financial Results
04/22/15
ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
Investor Downloads

Download Documentation Brigatinib Update at AACR: Overcoming Mechanisms of Resistance to other ALK TKIs in Preclinical Models
Download Documentation Brigatinib Update at AACR: Discovery of Brigatinib
Download Documentation Brigatinib Update at ELCC: Analysis of Safety and Efficacy at Selected Phase 2 Doses
Download Documentation Brigatinib Update at ELCC: Evaluation of Brigatinib in Patients with ALK+ NSCLC and Brain Metastases
Download Documentation Investor Presentation
More >>

ARIAD Stock Price: $9.71

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 04/24/15

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.10 (0.94%)
VOL5,506,244
OPEN$9.65
PREV. CLOSE$9.62
DAY HIGH$9.89
DAY LOW$9.54
52 WK. HIGH$9.67
Minimum 20 minute delay
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue